We recently used ARF6-TurboID (wild-type ARF6, not a GTP-preferential mutant) in high-grade serous ovarian cancer (HGSOC) cells to map the ARF6 interactome across an isogenic series of loss of TP53 and PTEN, alone or in combination [47]. Here, ARF6 is linked to ovarian serous adenocarcinoma.